Steatohepatitis/Metabolic Liver Disease News

Nonalcoholic steatohepatitis is the second leading indication for liver transplantation in the United States but there are currently no FDA-approved treatments available.

There is a significant medical need to find effective pharmacotherapies to manage NASH, the liver disease that is really a pandemic.

Ideal CV health behaviors were associated with lower nonalcoholic fatty liver disease, or NAFLD, prevalence among participants in the Multi-Ethnic Study of Atherosclerosis cohort.

Poxel announced additional positive phase 2a results and plans for a phase 2b trial of PXL770, an oral direct adenosine monophosphate-activated protein kinase activator intended for nonalcoholic steatohepatitis.

Lipid-lowering therapies, diabetes drugs and liver-related therapies are among the medication options for patients with nonalcoholic fatty liver disease, according to a presentation at the National Lipid Association Scientific Sessions.

Patients with non-alcoholic steatohepatitis treated with BIO89-100 experienced clinically meaningful reduction in liver fat, according to research presented at The Liver Meeting Digital Experience.

Patients treated with subcutaneous semaglutide experienced better resolution of non-alcoholic steatohepatitis without worsening fibrosis, according to the results of a placebo-controlled study presented at The Liver Meeting Digital Experience.

Malnutrition correlated with increased hospital mortality and infections in patients with alcoholic hepatitis, according to a presenter at The Liver Meeting Digital Experience.

New data showed favorable safety measures up to 48 weeks of treatment with tropifexor in nonalcoholic steatohepatitis, according to a presenter at The Liver Meeting Digital Experience.

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.